A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.
A new leukemia drug called ceralasertib combined with existing therapy shows clinical promise in treatment-resistant blood cancers with few options.
This Phase Ib/II trial evaluated ceralasertib, a novel ATR inhibitor, combined with azacitidine in patients with relapsed/refractory myelodysplastic syndromes or chronic myelomonocytic leukemia. The study demonstrated clinical responses and tolerability in a patient population with limited therapeutic options, supporting further development of ATR inhibition in myeloid malignancies.
What the study was
- Study design
- Phase Ib/II clinical trial
- Category
- Drug Development
- Maturity
- Validated
- Journal
- Blood Adv
Why it surfaced
First clinical data for ATR inhibitor class in R/R MDS/CMML; high unmet need population; published in Blood Advances by established MGH/WashU consortium.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.